How to Store MG132: Stability and Handling, Per the Research

What MG132 Is, in Research Terms

MG132 (carbobenzoxy-Leu-Leu-leucinal, frequently written Z-Leu-Leu-Leu-al) is a synthetic peptide aldehyde that acts as a reversible inhibitor of the 26S proteasome. It is a laboratory reagent with research use only status rather than an approved medicine, and it appears across the cell biology literature as a tool used to ask whether a given protein is cleared by the ubiquitin proteasome system. A 2026 review summarised research progress on the proteasome inhibitor MG132 in gynecologic malignant tumors, describing the compound as an investigational proteasome inhibitor studied in tumour models (PMID 41631982). A 2013 study in The FEBS Journal reported that the proteasome inhibitor MG-132 induced MCPIP1 expression, which illustrates that the molecule produces measurable cellular readouts when it is active (PMID 23551903).

Storage questions matter for a reagent like this because its biological readout depends on the chemical integrity of a reactive aldehyde group. Background on the compound itself is covered on the MG132 overview page, and broader handling principles for peptide reagents are collected in the guide to peptide storage.

Two Kinds of Evidence on This Page

It is worth being explicit about where the information in each section comes from, because the two categories are not equally strong.

• Compound specific published evidence. Peer reviewed articles that used MG132 and reported what happened in cells. These papers document biological activity and experimental use. None of the articles in the citation set below was designed as a stability or shelf life study of MG132, and none reports a storage temperature trial for the compound.
• General stability science and product labeling conventions. Chemistry that applies broadly to peptide aldehydes, lyophilised peptides and dimethyl sulfoxide (DMSO) stock solutions, plus the storage statements that commonly appear on certificates of analysis and reagent labels for this class of material. These are general principles, not findings specific to MG132, and are flagged as such throughout.

Does MG132 Need Refrigeration?

Reagent labeling for MG132 in its solid form conventionally specifies freezer storage rather than ordinary refrigeration, with minus 20 degrees Celsius listed most often for the powder and minus 20 or minus 80 degrees Celsius listed for prepared stock solutions in DMSO. That convention is a labeling statement rather than a published stability trial result; the research articles that used MG132, including the 2013 report that MG-132 induced MCPIP1 expression, describe experimental outcomes rather than the storage conditions that preserved the reagent (PMID 23551903).

The general chemistry behind cold storage for this class of compound is straightforward. Peptide aldehydes carry a reactive carbonyl at the C terminus, and that group is the same feature responsible for reversible proteasome inhibition. Reactive carbonyls are susceptible to oxidation toward the corresponding carboxylic acid, to hydration, and to reaction with nucleophiles present as trace contaminants. Lower temperature slows all of those processes. Refrigeration at 4 degrees Celsius slows them less than freezing does, which is why short term refrigeration is usually framed in labeling as a working condition rather than a long term storage condition for this material.

What refrigeration does not address

Cold storage does not remove moisture, oxygen or light. General peptide stability science describes humidity as a driver of hydrolysis in lyophilised material once a vial has been opened and allowed to equilibrate with room air, and describes repeated condensation on cold vials as a route for water to enter a solid. These are class level principles, not MG132 measurements.

Shelf Life: Solid Material Versus Stock Solutions

No shelf life figure for MG132 appears in the peer reviewed articles cited on this page. Reagent labeling for research chemicals typically assigns a retest or expiry date to the solid and a shorter recommended interval to solvent stocks, with the solid treated as the more stable form. The general reasoning is that in a dry solid the molecules are immobilised and reaction rates are low, while in solution the molecule is mobile, surrounded by solvent, and exposed to any dissolved oxygen or water present.

DMSO is the solvent most commonly named on MG132 labeling because the compound is poorly water soluble. DMSO is strongly hygroscopic, and general solution chemistry describes water uptake from room air as a progressive process that changes the effective solvent composition over time. Water in a DMSO stock increases the opportunity for hydrolysis and for hydration of the aldehyde group. This is general solvent science rather than an MG132 specific finding.

Room Temperature and Transit

Research chemicals in this class are frequently shipped at ambient temperature, on the general principle that a dry solid tolerates short excursions far better than a solution does. Transit tolerance is a different question from long term storage, and the distinction is not resolved by any published MG132 stability study. What the literature does establish is that MG132 remains biologically active in laboratories around the world when handled according to conventional cold chain practice, since papers using it continue to report proteasome dependent effects; for example, a 2025 study of the ubiquitin system targeting translocated EspH described proteasomal degradation of the bacterial effector (PMID 41340563), and a 2022 study reported that cellular PSMB4 protein suppressed influenza A virus replication by targeting the NS1 protein (PMID 36298834).

General stability science describes DMSO stocks as a particular concern during ambient transport for a non temperature related reason: DMSO freezes near 18.5 degrees Celsius, so a stock can be solid at cool room temperature and liquid in a warm room, and repeated phase change can concentrate solute unevenly if the vial is used without full remixing. Again, this is solvent behaviour rather than an MG132 result.

Freezing and Freeze Thaw Cycles

Aliquoting is the standard laboratory answer to freeze thaw exposure, and it appears throughout published methods sections for proteasome inhibitor work. The general principle is that each thaw allows condensation, oxygen exposure at the headspace, and local concentration gradients, and that splitting a stock into single use volumes limits the number of cycles any given portion experiences.

For the experiments themselves, consistency of inhibitor activity matters because many designs compare a treated sample against an untreated one and read out protein accumulation. A 2021 Bio-protocol article described analysis of protein stability by synthesis shutoff, a method family in which protein turnover is tracked after translation is halted (PMID 34909446). In designs of that type, a proteasome inhibitor that has lost potency can look like a biological absence of proteasomal turnover, which is why reagent integrity is treated as a methodological variable rather than a housekeeping detail.

Signs of Degradation: What Studies Report

The cited literature does not report visual or analytical degradation criteria for MG132 specifically. General peptide and small molecule handling practice describes several categories of indicator, presented here as class level chemistry rather than MG132 findings:

• Appearance changes in the solid. Clumping, caking or a shift from white to yellow or brown is commonly treated as a sign that moisture ingress or oxidation has occurred in lyophilised and crystalline peptide material.
• Appearance changes in solution. Visible particulates, cloudiness or colour change in a previously clear stock are treated as reasons for analytical re evaluation.
• Loss of functional readout. In practice, the most sensitive indicator for a proteasome inhibitor is the biological assay itself. Papers that use MG132 report accumulation of a substrate protein as evidence of proteasome dependence, as in a 2007 study showing that PIASy controlled ubiquitination dependent proteasomal degradation of Ets-1 (PMID 17456046) and a 2018 study on regulation of Gli2 stability by the deubiquitinase OTUB2 (PMID 30241937). A reagent that no longer produces the expected accumulation in a known positive control system is functionally suspect regardless of appearance.
• Analytical confirmation. Chromatographic and mass spectrometric purity checks are the methods used in the broader reagent quality literature to confirm whether degradation products have formed. No such analysis of aged MG132 appears in the papers cited here.

Why Reagent Integrity Shapes Interpretation

Proteasome inhibitors are often used alongside autophagy or other degradation pathway probes, and the direction of the conclusion can depend on whether each inhibitor worked. A 2021 study reported that fructose-1,6-bisphosphatase degradation in the methylotrophic yeast Komagataella phaffii occurred through the autophagy pathway (PMID 31903651), and a study of SUMO induced degradation of the polyglutamine protein ataxin-3 reported that autophagy mediated the effect (PMID 30460066). Studies of this design distinguish proteasomal from lysosomal routes, so an inactive proteasome inhibitor would bias the comparison. Related work on degradation machinery, such as a 2021 report on the role of the E3 ubiquitin ligase HRD1 in regulating serotonin transporter function (PMID 33243462) and a 2020 report that the p97 inhibitor CB-5083 blocked ERAD in Trypanosoma brucei (PMID 32735998), relies on the same logic of pathway specific blockade.

What the Published Record Does Not Answer

Several practical questions have no answer in the verified literature set: how long MG132 retains full potency at 4 degrees Celsius, how many freeze thaw cycles a DMSO stock tolerates before measurable potency loss, and what percentage of the aldehyde oxidises over a defined storage interval. These are empirical questions that would require dedicated stability testing, and the articles cited here were designed to study biology rather than reagent shelf life. Degrader chemistry papers such as a 2025 report on a ligand embedded photoswitching PROTAC for spatiotemporal tubulin degradation show how much attention the field gives to controlling when a degradation tool is active (PMID 41033078), but that work addresses light controlled activation rather than storage stability of MG132.

This page is for educational purposes only and is not medical advice; consult a licensed physician about any health decision. MG132 is a laboratory research chemical and is not an approved medicine for human use.

Related Reading

• MG132: what the research describes
• How to store peptides: general stability principles

References

• Research Progress of Proteasome Inhibitor MG132 in Treatment of Gynecologic Malignant Tumors (Journal of Biochemical and Molecular Toxicology, 2026)
• Proteasome inhibitor MG-132 induces MCPIP1 expression (The FEBS Journal, 2013)
• The ubiquitin system targets translocated EspH to proteasomal degradation (Gut Microbes, 2025)
• Cellular PSMB4 Protein Suppresses Influenza A Virus Replication through Targeting NS1 Protein (Viruses, 2022)
• Analysis of Protein Stability by Synthesis Shutoff (Bio-protocol, 2021)
• PIASy controls ubiquitination-dependent proteasomal degradation of Ets-1 (The Biochemical Journal, 2007)
• Regulation of Gli2 stability by deubiquitinase OTUB2 (Biochemical and Biophysical Research Communications, 2018)
• Fructose-1,6-bisphosphatase degradation in the methylotrophic yeast Komagataella phaffii occurs in autophagy pathway (Cell Biology International, 2021)
• Autophagy mediates SUMO-induced degradation of a polyglutamine protein ataxin-3 (Animal Cells and Systems, 2017)
• Role of the E3 ubiquitin ligase HRD1 in the regulation of serotonin transporter function (Biochemical and Biophysical Research Communications, 2021)
• p97 Inhibitor CB-5083 Blocks ERAD in Trypanosoma brucei (Molecular and Biochemical Parasitology, 2020)
• Ligand-embedded photoswitching PROTAC for spatiotemporal tubulin degradation (Bioorganic & Medicinal Chemistry, 2025)